Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siMcl-1
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
siMcl-1 (Myeloid Cell Leukemia 1 small interfering RNA) is a target-specific RNA interference (RNAi) agent designed to silence the expression of the anti-apoptotic protein Mcl-1. Mcl-1 is a member of the Bcl-2 family that plays a critical role in cell survival by inhibiting apoptosis, and its overexpression is frequently associated with chemotherapy resistance and poor prognosis in various cancers, including breast cancer, glioblastoma, and leukemia. By targeting and promoting the degradation of Mcl-1 mRNA, siMcl-1 reduces Mcl-1 protein levels, thereby lowering the apoptotic threshold and sensitizing cancer cells to cytotoxic therapies. While primarily utilized as a research tool in preclinical studies to investigate apoptotic pathways and drug resistance, siMcl-1 represents a therapeutic strategy for combination cancer therapies.
- Other names
- MCL1 siRNAMCL-1 siRNAMCL 1 siRNAMCL1-specific siRNAMCL-1-specific siRNAMCL 1-specific siRNAsmall interfering RNA targeting Mcl-1small interfering RNA targeting Myeloid Cell Leukemia 1
02
Targets
MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on siMcl-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siMcl-1.